BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Li H, Fu ZY, Arslan ME, Cho D, Lee H. Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: A comprehensive review. World J Exp Med 2021; 11(6): 79-92 [PMID: 36246150 DOI: 10.5493/wjem.v11.i6.79]
URL: https://www.wjgnet.com/2307-8960/full/v11/i6/79.htm
Number Citing Articles
1
Masashi Kono, Yoriaki Komeda, Hisato Kawakami, Satoru Hagiwara, George Tribonias, Kohei Handa, Shunsuke Omoto, Mamoru Takenaka, Hiroshi Kashida, Naoko Tsuji, Masatoshi Kudo. JAK Inhibitor Upadacitinib Induces Remission in Refractory Immune‐Related Colitis Triggered by CTLA‐4 and PD‐1 Inhibitor Combination Therapy in Malignant Pleural Mesothelioma: A Case ReportCancer Reports 2024; 7(10) doi: 10.1002/cnr2.70032
2
Maria Terrin, Giulia Migliorisi, Arianna Dal Buono, Roberto Gabbiadini, Elisabetta Mastrorocco, Alessandro Quadarella, Alessandro Repici, Armando Santoro, Alessandro Armuzzi. Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to ManagementInternational Journal of Molecular Sciences 2023; 24(14): 11504 doi: 10.3390/ijms241411504
3
O. Gómez Escudero. Enterocolitis and other immunotherapy and targeted therapy-related gastrointestinal manifestations: A review for gastroenterologistRevista de Gastroenterología de México (English Edition) 2024; 89(1): 89 doi: 10.1016/j.rgmxen.2023.11.001
4
Antonietta Gerarda Gravina, Raffaele Pellegrino, Alfonso Esposito, Marina Cipullo, Mario Romeo, Giovanna Palladino, Patrizia Iodice, Alessandro Federico, Teresa Troiani. The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative ReviewCancers 2024; 16(3): 611 doi: 10.3390/cancers16030611
5
O. Gómez-Escudero. Enterocolitis y otras manifestaciones de toxicidad gastrointestinal asociada a inmunoterapia y terapia blanco: una revisión para el gastroenterólogoRevista de Gastroenterología de México 2024; 89(1): 89 doi: 10.1016/j.rgmx.2023.11.001
6
Marianne Zoghbi, Kathryn J. Burk, Elio Haroun, Maria Saade, Maria Teresa Cruz Carreras. Immune checkpoint inhibitor-induced diarrhea and colitis: an overviewSupportive Care in Cancer 2024; 32(10) doi: 10.1007/s00520-024-08889-2
7
Sara Kiparizoska, Megan E. Murphy, Mark C. Mattar. Check this out: treatment paradigms in immune-checkpoint inhibitor colitisCurrent Opinion in Gastroenterology 2023; 39(1): 43 doi: 10.1097/MOG.0000000000000892
8
Casey Fazer-Posorske, Lisa Kottschade, Anna Schwecke. The Basics of Cancer Immunotherapy2024; : 179 doi: 10.1007/978-3-031-59475-5_14
9
Skaistė Astašauskaitė, Rita Kupčinskaitė-Noreikienė, Inga Zaborienė, Rūta Vaičiūnienė, Tomas Vanagas, Darius Pranys, Lina Poškienė, Elona Juozaitytė. Multiorgan Toxicity from Dual Checkpoint Inhibitor Therapy, Resulting in a Complete Response—A Case ReportMedicina 2024; 60(7): 1129 doi: 10.3390/medicina60071129
10
Andreja Ocepek. Colitis due to cancer treatment with immune check-point inhibitors – review of literature and presentation of clinical casesRadiology and Oncology 2024; 58(2): 179 doi: 10.2478/raon-2024-0022
11
Masaya Iwamuro, Takehiro Tanaka, Shunsuke Kagawa, Shoko Inoo, Motoyuki Otsuka. Collagenous Colitis in a Patient With Gastric Cancer Who Underwent ChemotherapyCureus 2023;  doi: 10.7759/cureus.39466
12
Angelo Del Gaudio, Federica Di Vincenzo, Valentina Petito, Maria Cristina Giustiniani, Antonio Gasbarrini, Franco Scaldaferri, Loris Riccardo Lopetuso. Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical ApproachInflammatory Bowel Diseases 2024; 30(6): 1018 doi: 10.1093/ibd/izad229